 This study evaluated the efficacy and safety of biosimilar rachuximab, RTX, in Pemphigus vulgaris, PV, patients, finding that it was associated with desirable outcomes in both newly diagnosed patients, NDPs, and previously treated patients, PTPs. First line use of RTX in NDPs was more effective and allowed a rapid tapering of corticosteroid doses compared to PTPs. This article was authored by Roha Tusi, Hamidriza Mahmoudi, Kamran Baligi, and others.